hVIVO (LSE:HVO) Additional Paid-In Capital : £0.52 Mil(As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is hVIVO Additional Paid-In Capital?

hVIVO's quarterly additional paid-in capital increased from Dec. 2022 (£0.00 Mil) to Jun. 2023 (£0.43 Mil) and increased from Jun. 2023 (£0.43 Mil) to Dec. 2023 (£0.52 Mil).

hVIVO's annual additional paid-in capital increased from Dec. 2021 (£0.00 Mil) to Dec. 2022 (£0.00 Mil) and increased from Dec. 2022 (£0.00 Mil) to Dec. 2023 (£0.52 Mil).

hVIVO Additional Paid-In Capital Historical Data

The historical data trend for hVIVO's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

hVIVO Additional Paid-In Capital Chart

hVIVO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

15.21

44.48

0.52

hVIVO Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															-	-	-	0.43	0.52

hVIVO Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

hVIVO Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of hVIVO's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

hVIVO (LSE:HVO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » hVIVO PLC (LSE:HVO) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

OPORF:USA HVO:Ireland ORPH:UK CRO:Germany

Address

42, New Road, Queen Mary Bioenterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.hvivo.com

hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences' Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.

hVIVO (LSE:HVO) Headlines

No Headlines